最新消息分類研發臨床進展

漢康-KY向TFDA提交 HCB303 IND 申請　推進三特異性免疫療法全球臨床開發 HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance

HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.

10 月 08, 2026

漢康-KY宣布 HCB303 IND 獲美國 FDA 同意　新一代三特異性免疫療法邁入臨床開發 HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.

10 月 03, 2026

漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day

HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.

9 月 23, 2026

漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026

HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).

9 月 18, 2026

漢康生技攜手 InSilicoTrials 推進 HCB101 AI 驅動臨床開發 HanchorBio Partners with InSilicoTrials to Advance AI-Driven Clinical Development for HCB101

HanchorBio announced that it has entered into a strategic memorandum of understanding (MOU) and an initial statement of work with InSilicoTrials Technologies S.p.A.

9 月 16, 2026

漢康生技 HCB101 達成臨床開發里程碑　美FDA 同意單一病人擴大使用（恩慈使用） HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as “safe to proceed”.

9 月 09, 2026

漢康-KY向美國 FDA 提交 HCB303 IND 申請　第二款三特異性免疫療法邁向臨床開發 HanchorBio Files U.S. IND for Second Trispecific Immunotherapy, HCB303

HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.

9 月 03, 2026

漢康生技擴展次世代免疫治療策略　整合免疫教育與巨噬細胞活化 HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation

HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.

8 月 20, 2026

漢康生技 HCB301 獲選 KSMO 2026 口頭報告　HCB101 胃癌研究榮獲最佳海報發表獎 HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026

HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.

8 月 19, 2026

漢康生技推進巨噬細胞導向免疫治療策略 HCB101 全球頭頸癌研究完成首位病人給藥 HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study

HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study

8 月 17, 2026